|
Variable
|
5-year OS rate (%)
|
P value
|
5-year PFS rate (%)
|
P value
|
|---|
|
Age (years)
| |
< 0.01
| |
0.02
|
|
≤ 60
|
66.7
| |
54.7
| |
|
> 60
|
42.1
| |
38.8
| |
|
Clinical stage
| |
< 0.01
| |
< 0.01
|
|
I–II
|
68.2
| |
61.7
| |
|
III–IV
|
50.7
| |
38.4
| |
|
B symptoms
| |
0.02
| |
< 0.01
|
|
No
|
63.8
| |
54.2
| |
|
Yes
|
48.7
| |
38.7
| |
|
Spleen involvement
| |
0.01
| |
< 0.01
|
|
No
|
62.4
| |
53.0
| |
|
Yes
|
41.8
| |
31.4
| |
|
IPI
| |
< 0.01
| |
< 0.01
|
|
< 3
|
64.4
| |
55.6
| |
|
≥ 3
|
41.9
| |
29.6
| |
|
LDH (U/L)
| |
< 0.01
| |
< 0.01
|
|
≤ 245
|
72.7
| |
60.1
| |
|
> 245
|
46.2
| |
39.0
| |
|
β2-MG (mg/L)
| |
< 0.01
| |
0.07
|
|
≤ 2.52
|
73.2
| |
54.6
| |
|
> 2.52
|
42.2
| |
35.7
| |
|
Rituximab
| |
0.04
| |
0.20
|
|
Without
|
53.1
| |
46.4
| |
|
With
|
71.9
| |
58.4
| |
|
First-line chemotherapy CR
| |
< 0.01
| |
0.04
|
|
No
|
49.1
| |
45.9
| |
|
Yes
|
72.2
| |
57.2
| |
|
PD-L1 expression in tumor cells
| |
0.02
| |
0.01
|
|
Negative
|
67.3
| |
59.6
| |
|
Positive
|
50.0
| |
39.6
| |
|
PD-L1 expression in tumor microenvironment
| |
0.21
| |
0.26
|
|
Negative
|
62.0
| |
52.5
| |
|
Positive
|
48.9
| |
39.3
| |
-
IPI international prognostic index, LDH lactate dehydrogenase, β2-MG β2-microglobulin, CR complete remission, PD-L1 programmed cell death-ligand 1
